Family of pain producing substances and methods to produce novel analgesic drugs

Abstract

A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).

1 . (canceled) 
     
     
         2 . A pharmaceutical composition for treating pain, shock, inflammatory conditions, or combinations thereof in a subject comprising one or more compounds that inhibit and/or minimize the production of oxidized linoleic acid metabolites and/or block the activity of oxidized linoleic acid metabolites and one or more pharmaceutically acceptable carriers. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the pharmaceutical composition comprises one or more compounds that block the activity of oxidized linoleic acid metabolites, wherein at least one of the compounds is an antibody that binds to at least one oxidized linoleic acid metabolite. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the antibody binds to a hydroxy linoleic acid metabolite. 
     
     
         5 . The pharmaceutical composition of  claim 3 , wherein the antibody binds to an epoxy linoleic acid metabolite. 
     
     
         6 . The pharmaceutical composition of  claim 3 , wherein the antibody binds to an oxo linoleic acid metabolite. 
     
     
         7 . The pharmaceutical composition of  claim 3 , wherein the antibody binds to one or more of: (10E,12Z)-9-oxooctadeca-10,12-dienoic acid; (9Z,11E)-13-oxooctadeca-9,11-dienoic acid; 9-hydroxyoctadecadienoic acid; 13-hydroxyoctadecadienoic acid; 9(10)-dihydroxy-octadec-12-enoic acid; 12,13-dihydroxy-9Z-octadecenoic acid; (12Z)-9,10-epoxyoctadecenoic acid; 12,13-epoxyoctadec-9Z-enoic acid. 
     
     
         8 . The pharmaceutical composition of  claim 3 , wherein the antibody is a monoclonal antibody. 
     
     
         9 . The pharmaceutical composition of  claim 3 , wherein the antibody is a polyclonal antibody. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition comprises one or more compounds that inhibit and/or minimize the production of oxidized linoleic acid metabolites. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition comprises one or more compounds that inhibit and/or minimize the production of oxidized linoleic acid metabolites, wherein at least one of the compounds is a cytochrome P-450 enzyme inhibitor. 
     
     
         12 . The pharmaceutical composition of  claim 9 , wherein the cytochrome P-450 enzyme inhibitor is ketoconazole. 
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition comprises one or more compounds that inhibit and/or minimize the production of oxidized linoleic acid metabolites, wherein at least one of the compounds is an antioxidant sufficient to substantially inhibit and/or reduce the catalytic effect of relevant metabolic enzymes in the Linoleate pathway. 
     
     
         12 - 24 . (canceled) 
     
     
         25 . The pharmaceutical composition of  claim 1 , wherein the composition comprises ketoconazole and nordihydroguaiaretic acid. 
     
     
         26 . pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition comprises up to about 10% by weight of ketoconazole.